ASCLEPIUS — Advancing scientific collaboration in phage therapy for treating Pseudomonas aeruginosa and Staphylococcus aureus

ASCLEPIUS’s overall aim is to boost the scientific excellence and innovation capacity of Giorgi Eliava Institute of Bacteriophagy, Microbiology and Virology (Eliava) and its high-quality Twinning partners - l’Institut national de recherche pour l’agriculture, l’alimentation et l’environnement, Universidade do Minho and Intelligentsia Consultants Sarl – to expand their insights in phage therapy for treating Pseudomonas aeruginosa and Staphylococcus aureus. To achieve this aim, ASCLEPIUS will implement a research and innovation strategy over three years based upon five objectives: Objective 1: Conduct exploratory research on phage therapy for treating Pseudomonas aeruginosa and Staphylococcus aureus. Objective 2: Transfer knowledge between experienced researchers of Eliava and the Twinning partners. Objective 3: Enhance career prospects of early-stage researchers of Eliava and the Twinning partners. Objective 4: Improve Eliava’s management and administrative capacity for European R&D programmes. Objective 5: Raise the research profile of Eliava and the Twinning partners.